Disclosures
Friedemann Paul, MD
| Scientific Advisory Boards | |
| Novartis OCTIMS study steering committee MedImmune / Viela Bio steering committee | |
| Funding for travel or speaker honoraria | |
| speaker honoraria and travel grants from Bayer, Novartis, Biogen Idec, Teva, Sanofi-Aventis / Genzyme, and Merck Serono, Alexion, Chugai, MedImmune, Shire, Roche, Actelion, Celgene | |
| Editorial Boards | |
| Academic Editor, PLoS ONE Associate Editor, Neurology Neuroimmunology and Neuroinflammation | |
| Consultancies | |
| consultancies for SanofiGenzyme, BiogenIdec, MedImmune, Shire, Alexion | |
| Research Support, Commercial Entities | |
| Research support from from Bayer, Novartis, Biogen Idec, Teva, Sanofi-Aventis / Genzyme, Alexion and Merck Serono | |
| Research Support, Government Entities | |
| German Research Council (DFG Exc 257), Werth Stiftung of the City of Cologne, German Ministry of Education and Research (BMBF Competence Network Multiple Sclerosis), Arthur Arnstein Stiftung Berlin, EU FP7 Framework Program (combims.eu) | |
| Research Support, Foundations and Societies | |
| Arthur Arnstein Foundation Berlin, Guthy Jackson Charitable Foundation, National Multiple Sclerosis Society of the USA | |